AHR and lung carcinoma: We found that CXCL13 was a direct target of AhR (Figure 3), and deficiency in CXCL13 or its receptor, CXCR5, abrogated BaP-induced lung cancer (Figure 4), while an anti-CXCR5 antibody significantly inhibited lung cancer cell migration (Figure 5).